Stryker price target raised to $326 from $290 at Citi

Citi analyst Joanne Wuensch raised the firm’s price target on Stryker to $326 from $290 and keeps a Buy rating on the shares. Most Q4 results in medical technology met expectations, which bodes well for the sector, the analyst tells investors in a research note. The analyst says the group has historically "worked" in a beat and raise environment and historically has been "recessionary resistant."